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Resveratrol is a naturally occurring polyphenol that activates SIRT1, an NAD-dependent
deacetylase. SRT501, a pharmaceutical formulation of resveratrol with enhanced sys-
temic absorption, prevents neuronal loss without suppressing inﬂammation in mice with
relapsing experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis
(MS). In contrast, resveratrol has been reported to suppress inﬂammation in chronic EAE,
although neuroprotective effectswere not evaluated.The current studies examine potential
neuroprotective and immunomodulatory effects of resveratrol in chronic EAE induced by
immunization with myelin oligodendroglial glycoprotein peptide in C57/Bl6 mice. Effects of
two distinct formulations of resveratrol administered daily orally were compared. Resvera-
trol delayed the onset of EAE compared to vehicle-treated EAEmice, but did not prevent or
alter the phenotype of inﬂammation in spinal cords or optic nerves. Signiﬁcant neuropro-
tective effects were observed, with higher numbers of retinal ganglion cells found in eyes
of resveratrol-treated EAE mice with optic nerve inﬂammation. Results demonstrate that
resveratrol prevents neuronal loss in this chronic demyelinating disease model, similar to
its effects in relapsing EAE. Differences in immunosuppression compared with prior stud-
ies suggest that immunomodulatory effects may be limited and may depend on speciﬁc
immunization parameters or timing of treatment. Importantly, neuroprotective effects can
occur without immunosuppression, suggesting a potential additive beneﬁt of resveratrol
in combination with anti-inﬂammatory therapies for MS.
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INTRODUCTION
Multiple sclerosis (MS) is an inﬂammatory demyelinating dis-
ease of the central nervous system (CNS) that can present with a
variable course of neurologic disability (Noseworthy et al., 2000).
Relapsing-remitting MS, the most common form of the disease, is
marked by intermittent episodes of focal neurologic dysfunction
that recovers as acute inﬂammation resolves. However, recovery
is often not complete, and it is now recognized that a signiﬁcant
amount of neurodegeneration also occurs in MS and correlates
with accumulation of permanent neurologic deﬁcits (Losseff et al.,
1996a,b; Trapp et al., 1998; Fisher et al., 2006). Other MS patients
follow a primary or secondary progressive disease course marked
by a slow neurologic decline due to axonal damage and loss of neu-
ronswithout discrete episodes of inﬂammation anddemyelination
(Noseworthy et al., 2000).
In both MS, and its animal model [experimental autoimmune
encephalomyelitis (EAE)], autoreactive T cells against myelin anti-
gens play a critical role in disease pathogenesis (Weiner et al.,
1984; Noseworthy et al., 2000; Lock et al., 2002; Gran et al., 2004).
The handful of MS medications that are available are all designed
to modulate the inﬂammatory component of the disease, but
most have limited effects on neurodegeneration and long-term
neurologic disability (Johnson et al., 1995; Jacobs et al., 1996;Hick-
man et al., 2003; Parry et al., 2003). Resveratrol, a polyphenolic
compound found in red grapes and other fruits, has numer-
ous potentially beneﬁcial effects including cardioprotection, anti-
oncogenesis, and anti-oxidant, as well as both anti-inﬂammatory
and neuroprotective effects in some systems that suggest it is a
good candidate therapy for MS (De La Lastra and Villegas, 2007).
We demonstrated that a pharmaceutical formulation of resver-
atrol (SRT501), with enhanced absorption that retains its normal
activity, prevents neuronal damage, and associated long-term neu-
rologic dysfunction in a relapsing-remitting EAE mouse model
(Shindler et al., 2007, 2010). The mechanism of these neuropro-
tective effects involves activation of SIRT1, an NAD-dependent
deacetylase involved in cell stress responses that has previously
been shown tobe activatedby resveratrol (Milne et al., 2007). Inter-
estingly, neither SRT501 nor other SIRT1 activating compounds
modulate inﬂammation in relapsing-remitting EAE (Shindler
et al., 2007, 2010), suggesting resveratrol has the potential to com-
plement current immunomodulatory MS therapies that fail to
prevent neurodegeneration.
In contrast to relapsing-remitting EAE effects, resveratrol
reportedly shows some immunosuppressive and immunomod-
ulatory effects in a chronic mouse EAE model (Singh et al.,
2007). However, the immunomodulatory effects were modest, and
neuroprotective effects were not evaluated. In addition, a differ-
ent puriﬁed unmodulated resveratrol formulation was used in
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these studies. Here we examine the potential neuroprotective and
immunomodulatory effects of puriﬁed resveratrol and SRT501 in
chronic EAE.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Six week old female C57/Bl6 mice were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA). Housing and treat-
ment of animals conformed to the Institutional Animal Care
and Use Committee Guidelines and review at the University of
Pennsylvania.
INDUCTION AND SCORING OF EAE
Experimental autoimmune encephalomyelitis was induced as
in our prior studies (Quinn et al., 2011). Brieﬂy, mice were
anesthetized with 0.2 ml solution containing 10 mg/ml ketamine
(Sigma, St. Louis, MO, USA) and 1 mg/ml xylazine (Sigma) i.p.
Mice were immunized with 300μg myelin oligodendroglial gly-
coprotein (MOG) peptide 35–55 (Invitrogen, Carlsbad, CA, USA)
emulsiﬁed in complete Freund’s adjuvant (CFA;Difco,Detroit,MI,
USA) containing 2.5 mg/ml mycobacterium tuberculosis (Difco),
divided into two doses injected subcutaneously at two separate
sites on the back. Control mice were injected with an equal vol-
ume of phosphate buffered saline (PBS) andCFA. EAE and control
mice received 200 ng pertussis toxin (List Biological, Campbell,
CA, USA) in 0.1 ml PBS by i.p. injection on the day of immu-
nization (day 0) and again on day 2. Clinical EAE was scored
daily by a blinded observer with a previously used ﬁve point
scale (Shindler et al., 2007, 2010; Quinn et al., 2011): no dis-
ease= 0; partial tail paralysis= 0.5; tail paralysis or waddling
gait= 1.0; partial tail paralysis and waddling gait = 1.5; tail paral-
ysis and waddling gait= 2.0; partial limb paralysis= 2.5; paralysis
of one limb= 3.0; paralysis of one limb and partial paralysis of
another= 3.5; paralysis of two limbs= 4.0; moribund state= 4.5;
death= 5.0.
RESVERATROL TREATMENT
The SRT501 (Sirtris, a GSK Company, Cambridge, MA, USA) for-
mulation of resveratrol (Milne et al., 2007; Shindler et al., 2010)
was suspended in 2% hydroxypropyl methylcellulose (Shin-Etsu
Chemicals, Japan) and 0.2% dioctyl sodium sulfosuccinate (Wil-
son Laboratories, Mumbai, India). Puriﬁed resveratrol purchased
from Sigma was suspended in PBS. Mice were treated by oral
gavage once daily with 100 mg/kg Sigma resveratrol, 250 mg/kg
Sigma resveratrol, 250 mg/kg SRT501 resveratrol, or PBS alone as
indicated in each experiment.
HISTOLOGY
Mice were transcardially perfused with PBS followed by 4%
paraformaldehyde. Spinal cords and optic nerves were removed,
post-ﬁxed in 4%paraformaldehyde, embedded in parafﬁn, and cut
in 5μm thick sections. For routine histological analysis, sections
were stained with hematoxylin and eosin (H&E) and examined
by light microscopy. The presence or absence of inﬂammatory
cell inﬁltrates, and relative degree of inﬂammation was scored
by a blinded investigator using a previously described 0–4 point
scale for optic nerves (Shao et al., 2004; Shindler et al., 2006):
no inﬁltration = 0, mild cellular inﬁltration of optic nerve or
optic nerve sheath = 1, moderate inﬁltration = 2, severe inﬁltra-
tion= 3, massive inﬁltration = 4; and 0–3 point scale for spinal
cords: no inﬂammation= 0; mild inﬂammation= 1, moderate
inﬂammation= 2, severe inﬂammation= 3.
RETINAL GANGLION CELL QUANTIFICATION
Retinal ganglion cells (RGCs) were labeled and quantiﬁed as
previously described (Shindler et al., 2007, 2010; Quinn et al.,
2011). Brieﬂy, RGCs were retrogradely labeled by injection of
2.5μl of 1.25%hydroxystilbamidine (Fluorogold; Invitrogen) into
the superior colliculi 1 week prior to EAE induction. Follow-
ing sacriﬁce, isolated, ﬁxed retinas were whole-mounted on glass
slides and viewed by ﬂuorescent microscopy. Photographs were
taken at 20X magniﬁcation in 12 standard ﬁelds: 1/6, 3/6, and
5/6 of the retinal radius from the center of the retina in each
retinal quadrant, and the number of RGCs was counted using
Image-Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA)
software.
PUPILLOMETRY
Pupillary light responses were induced and recorded similar to
prior studies using a Neuroptics Pupillometer (San Clemente, CA,
USA) for rodents (Hussain et al., 2009; Shindler et al., 2012). A
series of ﬁve ﬂashes of light at an intensity of 4.7μW/cm2,was used
to stimulate each eye and the pupillometer’s dual-camera system
measures changes in pupillary diameter of both eyes. Pupillary
constriction was determined by averaging the percentage change
in pupil diameter following each ﬂash of light. The highest and
lowest pupillary responses were discarded as potential outliers for
each eye, with the average of the remaining three responses used
for statistical comparisons.
OPTOKINETIC RESPONSES
Visual function was assessed by the optokinetic tracking response
(OKR) using OptoMotry software and apparatus (Cerebral
Mechanics), as described previously (Prusky et al., 2004; Quinn
et al., 2011). Brieﬂy,mice in a closed chamber are observed through
a camera to determine whether they are tracking a virtual cylinder
of a 100% contrast grating projected at varying spatial frequencies.
The highest spatial frequency at which mice track correlates with
visual acuity and is recorded as cycles/degree.
IMMUNOHISTOCHEMISTRY
Spinal cord sections were stained by the avidin–biotin-
immunoperoxidase technique (Vector Laboratories, Burlington,
CA, USA) using 3, 3′ diaminobenzidine as substrate, and antibod-
ies against lymphocytic cell markers, as in prior studies (Shindler
et al., 2011). Primary antibodies anti-CD3 mouse monoclonal
(Santa Cruz Biotechnology, Santa Cruz, CA,USA) diluted 1:200 in
PBS, anti-B220 Mouse monoclonal (BD Pharmingen, San Diego,
CA, USA) diluted 1:200, and anti-Iba1 rabbit polyclonal (Wako,
Richmond,VA,USA)diluted 1:200were used asmarkers forT cells,
B cells, and macrophages/microglia respectively. Anti-mouse or -
rabbit IgG secondary antibodies from the Vectastain ABC Mouse
Kit (Vector Laboratories) were used according to manufacturer’s
instructions.
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FLOW CYTOMETRY
Cells were isolated from EAE spinal cords and spleen by methods
described previously (Fitzgerald et al., 2007). Brieﬂy, following
transcardial perfusion with PBS, spleens, and spinal cords were
removed, spinal cords were pooled, and tissues were mechani-
cally dissociated through a 100-μm strainer and washed with PBS.
Resultant pellets were fractionated on a 60/30%Percoll gradient by
centrifugation at 300× g for 20 min. Mononuclear cells were har-
vested from the interface, washed, counted, and stained for 20 min
in the dark at 4˚C with ﬂuorescence-labeled antibodies speciﬁc for
cell surface markers. For intracellular markers, cells were washed,
ﬁxed and permeabilized with Fix & Perm reagents (Caltag Lab-
oratories) then stained with ﬂuorescence-labeled antibodies. All
antibodies (CD4, clone RM4-5; CD8, clone 53–6.7; IL-17, clone
TC11-18H10; IFN-gamma, clone XMG1.2) were purchased from
BD Bioscience and were used at a concentration of 0.5μg/ml.
Data were acquired on a FACSAria (BD Biosciences) and analyzed
with FlowJo software (Treestar) with cells gated based on physical
parameters (size and granularity).
STATISTICS
Clinical EAE scores were compared between treatment groups
by ANOVA for repeated measures using GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA). Comparisons of RGC
numbers, inﬂammation severity, and percentages of inﬂammatory
cell types were analyzed by one way ANOVA followed by Tukey’s
Multiple Comparison test using GraphPad Prism.
RESULTS
RESVERATROL DELAYS EAE ONSET
Experimental autoimmune encephalomyelitis was induced in
8 week old female C57/Bl6 mice by immunization with MOG
peptide (Quinn et al., 2011). Mice were treated orally daily for
30 days with puriﬁed resveratrol (RSV) at 100 or 250 mg/kg, doses
reported previously to suppress EAE (Singh et al., 2007). Addi-
tional EAE mice were treated with 250 mg/kg SRT501 resveratrol,
or with PBS alone. Mice treated with PBS developed a typical
course of chronic EAE, marked by ascending paralysis begin-
ning about 12 days after immunization, peaking several days later,
and then persisting (Figure 1). Treatment with 100 mg/kg RSV
failed to suppress EAE, whereas both RSV and SRT501 given at
250 mg/kg delayed the onset of EAE by several days, although
by 16–17 days post-immunization EAE severity reached levels
equivalent to PBS-treated mice (Figure 1).
RESVERATROL DOES NOT REDUCE CNS INFLAMMATION
Experimental autoimmune encephalomyelitis mice treated with
RSV, SRT501, or mock-treated with PBS were sacriﬁced on
day 30 post-immunization. Sections of spinal cords stained
by H&E were examined for areas of inﬂammatory cell inﬁl-
tration. Foci of inﬂammation were observed in the white
matter of EAE spinal cords, and similar inﬂammation was
detected in EAE spinal cords from mice treated with RSV
and SRT501 (Figures 2A–D). There was no difference in
the incidence of inﬂammation detected in RSV-, SRT501-,
FIGURE 1 | Resveratrol delays onset of EAE. Eight week old female
C57/Bl6 mice were immunized with MOG on day 0, and mice treated daily
by oral gavage with PBS, 100mg/kg RSV, 250mg/kg RSV, or 250mg/kg
SRT501 (N =5 mice/group). Mice were observed daily for clinical signs of
EAE and scored on a ﬁve point scale. No difference in EAE onset or
severity was found between PBS- or 100mg/kg RSV-treated EAE mice.
Treatment with 250mg/kg RSV or SRT501 both resulted in signiﬁcant
suppression of EAE at the onset of disease (days 12–16; *p<0.05) as
compared to EAE mice receiving PBS alone. One of two representative
experiments is shown.
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FIGURE 2 | Resveratrol does not suppress spinal cord inflammation.
Spinal cord sections from EAE mice were stained by H&E. (A) Spinal cord
from an EAE mouse treated with PBS alone shows foci of increased cellularity
in spinal cord white matter characteristic of inﬂammatory cell inﬁltrates
(arrows). Similar inﬂammation (arrows) is seen in spinal cords from EAE mice
treated with 250mg/kg RSV (B) and 250mg/kg SRT501 (C). (D) Spinal cord
from a control, non-EAE mouse demonstrates the normal cellularity without
inﬂammatory cell inﬁltration. (E)The percentage of spinal cord sections
containing inﬂammatory cell inﬁltrates did not differ between PBS-, RSV-, or
SRT501-treated EAE mice. Photos shown at original magniﬁcation ×20 (A–D).
and PBS-treated mouse spinal cords (Figure 2E). The aver-
age severity of spinal cord inﬂammation scored on a relative
scale was also not different between PBS-treated (1.24 ± 0.44,
N = 21), 100 mg/kg RSV-treated (1.40± 0.52,N = 10), 250 mg/kg
RSV-treated (1.27± 0.47, N = 11), or 250 mg/kg SRT501-treated
(1.36± 0.50, N = 11) EAE mice.
Optic neuritis, inﬂammatory demyelination of the optic nerve,
occurs frequently in MS (Arnold, 2005) and in almost all chronic
EAEmice (Shao et al., 2004;Quinn et al., 2011). To further examine
effects of resveratrol on EAE, optic nerve sections were exam-
ined. H&E staining demonstrated inﬂammatory cell inﬁltrates in
optic nerves from RSV-, SRT501-, and PBS-treated EAE mice,
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with no signiﬁcant difference in the incidence of optic neuritis
between treated and mock-treated mice (Figure 3). The sever-
ity of optic nerve inﬂammation, scored on a relative four-point
scale (Shindler et al., 2010; Quinn et al., 2011), also showed
no suppression of inﬂammation by RSV or SRT501, as differ-
ences in the degree of inﬂammation present in optic nerves
from PBS-treated (1.33± 0.49, N = 18), 100 mg/kg RSV-treated
(1.85± 0.89,N = 7), 250 mg/kg RSV-treated (1.14± 0.38,N = 7),
or 250 mg/kg SRT501-treated (1.56± 0.53,N = 9) EAE mice were
not statistically signiﬁcant (p = 0.10).
RESVERATROL REDUCES NEURONAL LOSS IN EAE MICE
Experimental autoimmune encephalomyelitis optic neuritis leads
to signiﬁcant loss of RGCs, the neurons that form the optic nerve,
and associated decreased visual function (Quinn et al., 2011). To
examine whether resveratrol can protect neurons from damage in
EAE, RGCs were retrogradely labeled with ﬂuorogold by injec-
tion into the superior colliculi 1 week prior to EAE induction
(Shindler et al., 2007, 2010; Quinn et al., 2011). Mice were treated
daily with RSV, SRT501, or mock-treated with PBS following
immunization, and control non-EAE mice were sham immunized
without peptide. RGC function was assessed by measuring pupil-
lary light responses using pupillometry (Hussain et al., 2009), and
visual acuity was estimated by OKR (Prusky et al., 2004). There
was a gradual decline in pupillary responses over the course of
4 weeks, with no differences observed between treated or mock-
treated EAE mice (Figure 4A). Visual function decline was also
observed in all treatment groups. Both RSV and SRT501 delayed
this loss of OKR responses at 2 weeks post-immunization, with
visual function signiﬁcantly better than in mock-treated EAE mice
(Figure 4B).
Retinal ganglion cells survival was assessed 30 days post-
immunization. The number of surviving RGCs was measured by
counting cells in 12 standardized ﬁelds on retinal whole mounts
(Shindler et al.,2007,2010;Quinn et al.,2011). Eyes fromEAEmice
mock-treatedwith PBShad signiﬁcantly fewerRGCs (335.8± 28.8
RGCs/eye) than control, non-EAE mice (529.2± 36.2), similar to
prior studies (Quinn et al., 2011). Eyes from EAE mice treated with
100 mg/kgRSV (458.8± 25.3),250 mg/kgRSV (529.2± 82.0), and
250 mg/kg SRT501 (464.6± 43.0) all had signiﬁcantly more RGCs
than eyes from mock-treated EAE mice (Figure 4C). Thus, on
average, untreated EAE mouse eyes lost 193.4 (36.5%) of their
RGCs, and treatment with 100 mg/kg RSV, 250 mg/kg RSV, and
250 mg/kg SRT501 reduced the amount of RGC loss by 64, 100,
and 66.5%, respectively.
RESVERATROL DOES NOT MODULATE PHENOTYPE OF CNS
INFLAMMATION
While results show that RSV and SRT501 both prevent neuronal
loss in EAE and delay neurologic dysfunction without suppress-
ing the gross level of inﬂammation that occurs in the spinal cord
and optic nerve, it is possible that resveratrol may reduce neu-
ronal damage by altering the type of inﬂammatory cells that
enter the CNS. To assess the basic types of inﬂammatory cells
present, sections of spinal cord from mock-, RSV-, and SRT501-
treated EAE mice were stained with markers of T cells (CD3),
B cells (B220), and macrophages/microglia (Iba1). Inﬂammatory
lesions in EAE spinal cord contained numerous T cells, as well as
macrophages,with little or no B cells present, similar to prior stud-
ies,demonstrating the ability of these antibodies to detect expected
cell types (Figure 5). To quantify the relative contribution of dif-
ferent cell types in spinal cord inﬁltrates, the presence of each type
FIGURE 3 | Resveratrol does not suppress optic nerve inflammation.
Optic nerve sections from EAE mice were stained by H&E. (A) Normal
cellularity of a control, non-EAE optic nerve without inﬂammation is shown.
(B) Optic nerve from an EAE mouse treated with PBS alone shows foci of
inﬂammatory cell inﬁltrates (arrows) within the optic nerve and optic nerve
sheath. Similar inﬂammation (arrows) is seen in optic nerves from EAE mice
treated with 100mg/kg RSV (C), 250mg/kg RSV (D), and 250mg/kg SRT501
(E). (F)The percentage of inﬂamed optic nerves did not differ between PBS-,
RSV-, or SRT501-treated EAE mice. Photos shown at original magniﬁcation
×40 (A–E).
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FIGURE 4 | Resveratrol prevents neuronal loss and delays visual
decline. (A)The average degree of pupillary constriction in response to
ﬂashes of light measured by pupillometry decreased over the ﬁrst 2weeks
after immunization in EAE mice, with no difference between EAE mice
treated with PBS, 100mg/kg RSV, 250mg/kg RSV, or 250mg/kg SRT501.
(B) Visual function, measured by OKR responses, was signiﬁcantly reduced
in EAE mice treated with PBS as compared to those treated with either
100mg/kg RSV, 250mg/kg RSV, or 250mg/kg SRT501 at 2weeks
post-immunization (*p<0.05). (C) At day 30 post-immunization, there was
a signiﬁcance decrease in the number of RGCs counted in each retina of
EAE mice treated with PBS (vehicle) alone, as compared to control,
non-EAE mice, and compared to EAE mice treated with RSV or SRT501
(*p<0.05).
FIGURE 5 | Inflammatory cell types detected in EAE spinal cord. (A)
Section of a representative EAE spinal cord 30 days post-immunization
stained with antibodies to CD3 shows numerousT cells mainly within the
white matter (arrow). (B) An adjacent section stained with Iba1 antibodies
demonstrates numerous macrophages/microglia in the same inﬂammatory
focus (arrow) in the white matter, as well as individual microglia across the
spinal cord white matter and gray matter (arrowheads). (C) Adjacent section
stained with B220 antibodies shows B cells do not contribute signiﬁcantly
to observed foci of inﬂammation. Photos shown at original magniﬁcation
×20 (A–C).
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of inﬂammatory cell, and the relative level of inﬂammation, was
score by a blinded investigator. No signiﬁcant difference in the
amount of inﬂammation by each cell type was observed between
RSV-, SRT501-, or mock-treated mice (Table 1).
To further examine the phenotype of inﬂammation, mononu-
clear cells were isolated from the spinal cords of EAE mice and
analyzed by ﬂow cytometry, and cells isolated from the spleen were
analyzed to assess effects on T cells in the periphery. Results show
no signiﬁcant differences in the percentage of CD4+ vs. CD8+
T cells present in spinal cords or spleens from RSV-, SRT501-,
or mock-treated EAE mice (Figure 6). As both interferon(IFN)-
gamma+ Th1 effector T cells and IL-17+ Th17 effector T cells
have been implicated as the pathogenic cells in EAE (Langrish
et al., 2005; Steinman, 2008; Stromnes et al., 2008), we also exam-
ined the expression of these cytokines in CNS and peripheral T
cells. The proportion of IFN-gamma and IL-17 expressing T cells
was limited to less than 10% in the spleen and was only slightly
higher in spinal cord. Notably, no differences were found between
treated and mock-treated mice (Figure 6).
DISCUSSION
Results demonstrate that oral SRT501 resveratrol prevents neu-
ronal damage in chronic EAE, similar to the neuroprotective
effects observed previously in relapsing-remitting EAE (Shindler
et al., 2010). SRT501 effects on RGCs are robust, eliminating two-
thirds of the RGC loss induced by EAE optic neuritis. Effects
are not speciﬁc to SRT501, but are also induced by unmodi-
ﬁed, puriﬁed resveratrol. As in the relapsing-remitting EAE model,
the mechanism of these neuroprotective effects does not involve
Table 1 | Levels of Iba1+ macrophages/microglia, CD3+T cells, and
B220+ B cells detected in EAE spinal cords.
Iba1
− ± + ++
EAE PBS 0% (0/12) 8% (1/12) 58% (7/12) 33% (4/12)
EAE RSV 0% (0/9) 11% (1/9) 44% (4/9) 44% (4/9)
EAE SRT501 0% (0/9) 0% (0/9) 44% (4/9) 56% (5/9)
CD3
− ± + ++
EAE PBS 36% (4/11) 27% (3/11) 27% (3/11) 9% (1/11)
EAE RSV 44% (4/9) 22% (2/9) 22% (2/9) 11% (1/9)
EAE SRT501 11% (5/9) 22% (2/9) 56% (5/9) 11% (1/9)
B220
− ± + ++
EAE PBS 55% (6/11) 45% (5/11) 0% (0/11) 0% (0/11)
EAE RSV 89% (8/9) 11% (1/9) 0% (0/9) 0% (0/9)
EAE SRT501 56% (5/9) 44% (4/9) 0% (0/9) 0% (0/9)
(−), no stained cells observed; (±), equivocal staining with just a few rare positive
cells present; (+), scattered deﬁnitively positive staining cells in spinal cord white
matter; (++), discreet foci of positive cells. The percentage of spinal cords from
EAEmice treatedwith PBS, 250mg/kg RSV, or 250mg/kg SRT501 for 30 days that
demonstrated each level of staining on immunohistochemistry is shown. Num-
bers in parentheses indicate the number of spinal cords receiving each score/total
number examined.
FIGURE 6 | Resveratrol does not suppressT cells in the periphery or
CNS.Total cells were isolated from the spleens of individual EAE mice
treated with PBS alone, 100mg/kg RSV, 250mg/kg RSV, or 250 SRT501
daily until day 30 post-immunization. (A) Freshly isolated cells stained with
antibodies to CD4 and CD8 were analyzed by ﬂow cytometry.
Representative plot for one mouse in each treatment group shows
identiﬁable populations of CD4+ and CD8+T cells. (B)The average
percentage of CD4+ and CD8+T cells found in EAE spleens (N =4
mice/treatment group), and the percentage of CD4+ cells that stained
positive for IL-17 and IFN-gamma, is shown. No difference is observed
between treatment groups. (C) Spinal cords from mice in each treatment
group (N =4) were pooled together to ensure sufﬁcient numbers of
inﬂammatory cells for ﬂow cytometry. Less than 10% of spinal cord
mononuclear cells from each treatment group were CD4+T cells. Within
the CD4+T cell population, 5–15% were IL-17+ and 10–20% were
IFN-gamma+, with too few cells present for statistical analysis.
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signiﬁcant long-term suppression or modulation of inﬂamma-
tion, as the level of inﬂammation and type of cells present was not
altered by resveratrol during the chronic stage of EAE examined
in these studies. In addition to preventing loss of neurons, at daily
doses of 250 mg/kg both resveratrol compounds signiﬁcantly delay
the development of neurologic dysfunction – ascending paralysis
marked by EAE score, and visual function measured by OKR.
Despite observed neuroprotective effects, resveratrol’s ability
to prevent paralysis and vision loss is limited in this chronic
autoimmune disease. Within several days of the onset of symp-
toms, EAE severity and visual decline worsen to levels similar
to those in mock-treated EAE controls. This eventual accumu-
lation of neurologic deﬁcits likely is due to the chronic inﬂamma-
tory nature of this model. Indeed, by 30 days post-immunization,
RSV-, SRT501-, and mock-treated EAE mice all have similar lev-
els of spinal cord and optic nerve inﬂammation which may be
directly interferingwith nerve functiondespite improvedneuronal
survival. Similar ﬁndings were observed in relapsing-remitting
EAE mice treated with SRT501 (Shindler et al., 2010), where
SRT501 failed to improve neurologic function during the acute
inﬂammatory phase of disease, but in those mice SRT501 treat-
ment did signiﬁcantly improve neurologic function during the
remission phase of disease, after inﬂammation resolved. The cur-
rent results demonstrating the ability to maintain neurons up to
30 days post-immunization despite ongoing inﬂammation sug-
gests that resveratrol has the potential to delay neuronal loss for
longer periods of time during exposure to damaging inﬂamma-
tion, and may be capable of maintaining neurons while wait-
ing for current immunomodulatory MS medications to success-
fully suppress active inﬂammation. This is particularly impor-
tant for MS because permanent neurologic disability that affects
many MS patients occurs secondary to neuronal loss (Losseff
et al., 1996a,b). The ability of resveratrol to protect RGCs sug-
gests the potential for improved visual outcomes following optic
neuritis, where it has been well documented that RGC axonal
loss correlates with vision loss (Steel and Waldock, 1998; Parisi
et al., 1999; Trip et al., 2005; Costello et al., 2006; Fisher et al.,
2006).
Unlike prior studies (Singh et al., 2007) that reported sus-
tained suppression of EAE using the same 100 and 250 mg/kg
doses tested here, we found only a delay in EAE development
with the higher dose of resveratrol. This difference may be due
to higher concentration of MOG used to induce a more robust
EAE disease course in the current studies. While Singh’s stud-
ies (Singh et al., 2007) reported some decrease in spinal cord
inﬂammation, the level of inﬂammation was not quantiﬁed and
the sections they showed demonstrated that obvious foci of
inﬂammation still occurred in EAE spinal cords after resveratrol
treatment, similar to our ﬁndings. Singh did demonstrate some
changes in serum levels of cytokines 25 days post-immunization,
although the IL-17 cytokine felt to be critical in EAE was not
signiﬁcantly affected by resveratrol treatment at day 25 despite
earlier effects at day 9 (Singh et al., 2007). Those studies did
not evaluate inﬂammatory cell types or cytokine proﬁles in the
CNS, the site of damage in EAE. Our current results therefore
examined this, and found no signiﬁcant effects of resveratrol.
Together, results do suggest resveratrol may have some mod-
est immunomodulatory effects at some points in the course of
autoimmune demyelinating disease, but its neuroprotective effects
are most prominent.
Another studydemonstrated some immunomodulatory effects,
altering the percentage if IL-17 positive T cells in the periph-
ery and CNS following long-term resveratrol treatment in the
relapsing-remitting EAE model (Imler and Petro, 2009). How-
ever, like our prior studies, they also saw little effect during the
ﬁrst acute episode in the relapsing-remitting disease, only not-
ing some suppression after multiple relapses. Resveratrol may
therefore have some long-term immunomodulatory effects itself
that could have additional beneﬁts in EAE and MS. Future
studies in both EAE models using combination therapy with
resveratrol and current immunomodulatory MS medications
will be useful to determine whether resveratrol can enhance
their immunosuppressive effects, and retain its own important
neuroprotective effects.
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